New York, New York--(Newsfile Corp. - January 21, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfala ...

Core Insights - ENvue Medical, Inc. has appointed Marc Waldman as Vice President, Commercial to lead its U.S. commercialization strategy and expand its presence in 38 hospitals [1][2] - Waldman brings over 35 years of experience in the medical device industry, having previously increased revenue from approximately $39 million to $70 million during his tenure as North America Sales Director at Avanos Medical [2] - The company specializes in non-invasive solutions for enteral care, with a focus on advancing patient safety and clinical usability [3][4] Company Overview - ENvue Medical, Inc. is headquartered in Tyler, Texas, and focuses on intelligent, non-invasive solutions for enteral care across clinical and home care settings [3] - The company operates two distinct technology platforms, including the ENvue™ Navigation Platform, which assists in placing feeding tubes and is FDA 510(k) cleared for adult use [4] - ENvue Medical also develops acoustic-based therapeutic technologies aimed at treating pain and reducing bacterial colonization [4]

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is included on our list of the best undervalued wide moat stocks. Zimmer Biomet Holdings (ZBH)'s 2026 Expectations Remain Cautious Amid Internal Reset On January 13, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) laid out cautious expectations for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, according to The Fly. While we don’t have specific details at this time, the company said its guidance will reflect the scale of the internal changes it has planne ...

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is included on our list of the best undervalued wide moat stocks. Zimmer Biomet Holdings (ZBH)'s 2026 Expectations Remain Cautious Amid Internal Reset On January 13, 2026, Zimmer Biomet Holdings, Inc. (NYSE:ZBH) laid out cautious expectations for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, according to The Fly. While we don’t have specific details at this time, the company said its guidance will reflect the scale of the internal changes it has planne ...

LE PONT-DE-CLAIX, France and BURGDORF, Switzerland, Jan. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopakâ"¢ XtraFlowâ"¢ Glass Prefillable Syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, expanding options for pharmaceutical comp ...

Core Insights - Sisram Medical Ltd has entered into a memorandum of understanding with Sinmait Medical Technology to enhance localization efforts in China, which is expected to accelerate its strategic implementation and business expansion in the Chinese market [1][2]. Group 1: Partnership and Localization - The partnership with Fosun Pharma will allow Sisram to leverage advanced production capabilities and local expertise to establish a manufacturing hub in China, initially focusing on Energy-Based Devices (EBD) [3]. - The new facility will cater to domestic demand and serve as a strategic center for the APAC region, addressing the growing need for scalable production and advanced research and development [4]. Group 2: Strategic Vision and Market Position - The collaboration elevates Sisram's localization strategy in China, aiming to build a comprehensive and competitive localized ecosystem, which is a key milestone in the company's vision of "In China, for Global" [5]. - The synergistic development and localized manufacturing of EBD alongside other product offerings will enhance the portfolio's effectiveness, providing Chinese consumers with superior and accessible domestic wellness solutions [5]. Group 3: Company Overview - Sisram Medical Ltd is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD), serving customers in over 110 countries and regions [6]. - The company has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017 and is majority-owned by Fosun Pharma [6].

Shutthiphong Chandaeng/iStock via Getty Images By Jeffrey Bailin, CFA & Aram Green An Uneven 2025 Gives Way to a Hopeful 2026 Market Overview In many respects, 2025’s market resembled the preceding two years. We entered each with conditions that seemed poised to set the stage for the end to the longest losing streak on record for small caps versus large caps and hopes for a broadening out of growth sectors. However, this turned out to be another narrowly driven year of narratives, strong performance for ...

摘要 ： 基于国家药品监督管理局（NMPA）官网公开信息，仪器信息网对 2025 年度获得医疗器械注册证的质谱相关产品进行了盘点，并结合近六年获批数据， 试图剖析中国临床质谱产业正在发生的变化。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在此前的盘点中，仪器信息网已对2 0 2 5年度质谱新品进行了系统梳理 （点击查看： 质谱仪该以什么形态服务产业？这3 5款新品给出答案 ） 。本篇将进一步聚焦临床应用端，基于国家药品监督管理局（NMPA）官网公开信息，对2 0 2 5年度获得医疗器械注册证的质谱仪器、质谱相关 试剂盒及校准品进行全面盘点，并结合近六年获批数据，试图剖析中国临床质谱产业正在发生的变化。 六年回溯，格局变化显著 回顾2 0 2 0 - 2 0 2 5年中国市场新增获批的临床质谱仪器 （注：数据统计截止 2 0 2 5 年 1 2 月 3 1 日） ，清晰的展现出一个现象：国产质谱医疗器械的 合规化进程，已经完成了从"起步"到"放量"的阶段。 自2 0 2 0年起，国产质谱医疗器械注册证获批数量持续增长，并在2 0 2 3 ...

Core Insights - Senzime AB has secured a strategic contract with a leading Ivy League university hospital system in the US [1] - The initial phase of the contract involves the installation of 60 next-generation TetraGraph systems [1] - Full implementation is expected to result in the usage of over 10,000 disposable sensors annually from these monitors [1]

Anteris Technologies Global Corp. (NASDAQ:AVR) shares jumped 52.17% in after-hours trading on Tuesday, reaching $8.75, following the announcement of a major capital raise.According to Benzinga Pro data, AVR closed the regular session at $5.75, up 12.52%.$200 Million Public Offering AnnouncedThe Brisbane-based structural heart company announced plans for a $200 million underwritten public offering of common stock, according to a Monday press release. Underwriters were granted a 30-day option to purchase an a ...